OnKure's Convertible Note Round

OnKure raised a round of funding on July 07, 2015.

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In preclinical models of both …

Articles about OnKure's Convertible Note Round: